HIF‐1α triggers long‐lasting glutamate excitotoxicity via system xc− in cerebral ischaemia–reperfusion. Issue 3 (29th December 2016)

• Record Type: Journal Article
• Authors: Hsieh, Chia‐Hung; Lin, Yu‐Jung; Chen, Wei‐Ling; Huang, Yen‐Chih; Chang, Chi‐Wei; Cheng, Fu‐Chou; Liu, Ren‐Shyan; Shyu, Woei‐Cherng
• Is Part Of: Journal of pathology. Volume 241:Issue 3(2017)
• Page Start: 337
• Page End: 349
• Publication Date: 2016-12-29
• Subjects: hypoxia‐inducible factor 1α -- N‐methyl‐d‐aspartate receptor -- system xc− -- cerebral ischaemia–reperfusion -- sorafenib; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.4838
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Hypoxia‐inducible factor 1α (HIF‐1α) controls many genes involved in physiological and pathological processes. However, its roles in glutamatergic transmission and excitotoxicity are unclear. Here, we proposed that HIF‐1α might contribute to glutamate‐mediated excitotoxicity during cerebral ischaemia–reperfusion (CIR) and investigated its molecular mechanism. We showed that an HIF‐1α conditional knockout mouse displayed an inhibition in CIR‐induced elevation of extracellular glutamate and N ‐methyl‐d ‐aspartate receptor (NMDAR) activation. By gene screening for glutamate transporters in cortical cells, we found that HIF‐1α mainly regulates the cystine–glutamate transporter (system xc − ) subunit xCT by directly binding to its promoter; xCT and its function are up‐regulated in the ischaemic brains of rodents and humans, and the effects lasted for several days. Genetic deletion of xCT in cortical cells of mice inhibits either oxygen glucose deprivation/reoxygenation (OGDR) or CIR‐mediated glutamate excitotoxicity in vitro and in vivo . Pharmaceutical inhibition of system xc − by a clinically approved anti‐cancer drug, sorafenib, improves infarct volume and functional outcome in rodents with CIR and its therapeutic window is at least 3 days. Taken together, these findings reveal that HIF‐1α plays a role in CIR‐induced glutamate excitotoxicity via the long‐lasting activation of system xc − ‐dependent glutamate outflow and suggest that system xc − is a promising therapeutic target with an extended therapeutic window in stroke. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.